Introduction
Angioedema (AE) is defined as localized and transient edema of the deep skin layers or the upper respiratory or gastrointestinal mucosa. This condition involves the reticular (deep) dermis and subcutaneous and submucosal tissues. Angioedema is due to a temporary increase of the vascular permeability caused by vasoactive mediators. It frequently occurs as part of urticaria, but when angioedema occurs without wheals, it can sometimes manifest with symptoms of pain and tenderness, whereas itching may not be present [1] . Although the most common sites of involvement are the tongue, lips, face, and throat, angioedema may also occur in the extremities, genitalia, and viscera, and it could also be life-threatening when affecting the airway, requiring immediate treatment [2••] .
This review is focused in angioedema without wheals (AE-WoW) and highlights the pathophysiology of the most important types of angioedema without wheals and the special role of mast cell in these types. Recently, published classifications of AE-WoW are discussed, and a new proposal is suggested. Finally, it gives an overview on the novel therapies for different types of angioedema.
The classification of angioedema without wheals
Although angioedema is frequently associated with urticaria, it can also occur alone in 10-15 % of the cases [3, 4•] . Like urticaria, angioedema results from increased vascular permeability caused by the release of vasoactive mediators. The difference between both conditions lies in the dermis layer where leakage and transudation of plasma occur; urticaria affects the superficial skin layers (papillary dermis), whereas angioedema involves the deeper reticularis dermis, subcutaneous tissue, and the submucosa.
The pattern of swelling is an important diagnostic consideration as well as the association with urticaria. Classically, angioedema without wheals had been classified as bradykinin (BK) or histamine-mediated. Nevertheless, the implication of these vasoactive substances has only been demonstrated in a few patients. An increase of plasma BK has been observed locally during angioedema attacks in hereditary angioedema with C1 inhibitor deficiency (HAE-C1INH), acquired angioedema with C1 inhibitor deficiency (AAE-C1INH) and in angioedema due to angiotensin converting enzyme inhibitors (ACEi) [5, 6] . The term histamine-mediated angioedema was established on the basis of the therapeutic response to antihistamines. In 2013, the Hereditary Angioedema International Working (HAWK) group proposed a new classification of angioedema distinguishing hereditary from nonhereditary forms [2••] . The term BK-mediated was avoided because of the lack of evidence of the implication of BK (BK) in most types of angioedema. Moreover, other vasoactive substances such as substance P, cystenil leukotrienes, or prostaglandins are also implicated in the generation of angioedema. On the other hand, mast cell heparin can activate contact system and the release of BK [7••, 8] .
Recently, a new classification based on endotypes has been proposed [9] . In this classification, the different types of angioedema are divided into three groups: those due to an excess of BK, those due to mast cell and basophil degranulation, and a third group (idiopathic). This classification includes other types of angioedema such as NSAID induced or exacerbated angioedema, allergic angioedema, or drug-induced angioedema. However, BK involvement in hereditary angioedema with normal C1 inhibitor (HAE-nC1INH) has not been demonstrated, although it is assumed because of the clinical similarity to angioedema due to C1INH deficiency and the response to drugs targeting BK [10] .
We propose a modification (Fig. 1 ) of the HAWK classification that includes allergic angioedema and NSAID-induced angioedema. In this classification, the currently known pathogenic mechanisms are considered. Although the mechanism of idiopathic angioedema that does not response to antihistamines is currently unknown, a BK-related mechanism seems to be involved in its pathogenesis, and experimental evidence is still limited.
Clinically, BK-related angioedema (hereditary and acquired C1INH deficiency and ACEi-angioedema) and HAE with normal C1INH are slow in both onset and progression and usually last more than 24 h. In contrast, mast cell or basophil-related angioedema is quickly established and lasts G24 h. Prevention with antihistamines and speed of onset are nowadays the only clues to diagnose an idiopathic angioedema due to mast cell/basophil activation (histaminergic idiopathic angioedema or idiopathic angioedema that responds to antihistamines) because of the lack of an effective biomarker to differentiate it from unknown or nonhistaminergic angioedema.
Mechanisms of angioedema without wheals
Mast cell-mediated angioedema is pathophysiologically similar to urticaria, although it takes place in deeper levels of the dermis and involved mediators are probably different. With the exception of angioedema due to C1INH deficiency, the pathophysiology of angioedema without wheals is not completely clear. The central effector cell is the dermal or mucosal mast cell which upon activation releases vasoactive mediators such as histamine, prostaglandins, or leukotrienes contributing to the early and late responses [11] with extravasation of fluid into the superficial tissues in urticaria and in the deeper layers of the skin in angioedema. Factors determining the association of AE to urticaria or not are largely unknown.
Mast cell and basophil-related angioedema
The major immunological pathway related with mast cell activation is IgEmediated type I hypersensitivity. However, in most patients, angioedema is developed without an interaction between IgE bound to mast cells and allergens. In the case of urticaria, the binding of IgG auto-antibodies to IgE and/or to the high affinity receptor for IgE on mast cells has been shown to be the mechanism of activation of mast cell in some patients with chronic spontaneous urticaria (CSU) [12] . This autoimmune or auto-reactive urticaria represents up to 50 % of patients with chronic urticaria. Mast cell activation can also result from type III hypersensitivity through the binding of circulating immune complexes to mast cells/expressing Fc receptors for IgG and IgM [12] . Activation of mast cells can also occur through T cells, membrane receptors involved in innate immunity (anaphylotoxins, Toll-like receptors), or by direct toxicity of drugs or haptens.
NSAIDs can induce angioedema through IgE and non-IgE-mediated hypersensitivity reactions. The latter is linked to the NSAIDs inhibition of cycloxygenaxe-1 (COX-1) leading to an overproduction of cysteinyl-leukotrienes, by increasing the metabolism of arachidonic acid through COX-2 [13] . All NSAIDs inhibiting COX-1 can induce symptoms, and cross-reactions are independent of their chemical structure. Cysteinyl-leukotrienes are vasoactive substances able to increase vascular permeability.
Bradykinin-related angioedema
C1-INH prevents uncontrolled activation of factor XII and directly inhibits kallikrein, the enzyme inducing the excision of BK from high-molecular-weight kininogen [14] . Therefore, in HAE-C1INH and AAE-C1INH, the most potent inhibitor of the contact system, decreased activity of C1-INH, results in increased quantities of BK, a vasoactive peptide that is thought to be the primary mediator of swelling in HAE. Accumulation of BK results in increased vascular permeability, vasodilation, and contraction of nonvascular smooth muscle, resulting in the clinical symptoms of HAE [15] .
Although the mechanism of ACEi-induced AE (ACEi-AAE) is not fully understood [16] , it has been associated with the disability of BK, des-Arg 9 -BK, and SP degradation related with ACE inhibition [17] . In one study, high levels of BK were reported in ACEi-AAE patients [18] .
Possible bradykinin-related angioedema
The pathogenic mechanism by which angioedema is produced in HAEnC1INH is uncertain. The presence of factor XII mutations suggested an increase in contact system activation and a pathogenic role of BK. Nevertheless, the implication of BK in this type of angioedema has not been proven. In most cases, HAE-nC1INH angioedema attacks occur under hyper-estrogenic situations such as pregnancy or use of oral contraceptives. Estrogens can raise BK levels, either increasing its production or altering its degradation. C1INH activity is normally decreased in pregnant women. In addition, increased levels of factor XII have been observed in women taking estrogenic contraceptive pills with high levels of estrogens [19, 20] . Estrogens also increase B2-R gene expression and function [21] . On the other hand, estrogens suppress ACE expression, increasing BK and des-Arg9-BK concentrations [22] . This potential mechanism involved in this type of angioedema has been described recently by Kaplan et al. [23] .
However, in the last years, a possible activation of BK-forming cascade in a factor-XII independent way has also been described. This could also have implications in the pathogenesis of hereditary angioedema type I and II [24] .
The exact mechanism of idiopathic angioedema that does not respond to antihistamines remains currently unidentified.
Mast cell mediators involved in angioedema
Mast cells mediators traditionally have been divided in three groups: (1) preformed mediators stored in the cytoplasmic granules released by degranulation (i.e., histamine, tryptase, chymase, carboxypeptidase A and proteoglycans), (2) newly generated proinflammatory lipid mediators (i.e., prostaglandins, leukotrienes, and platelet activating factor (PAF)), and (3) newly synthesized growth factors, cytokines, and chemokines.
The exact effects of each of these mediators are not fully known, although the main actions have been reported. However, the interpretation of these available data is also hampered by the fact that key steps occur locally at the site of initial contact and mediators from this component will not be detectable systemically. Furthermore, the potency of each mediator varies enormously, some of them being 1000 times more potent than others regarding vascular effects, and many pathways are redundant and overlapping, hindering the understanding of the exact role of each mediator. Therefore, antagonizing any single mediator alone is unlikely to render a significant therapeutic effect [25] . Table 1 summarizes the main mediators of mast cells possibly involved in angioedema and their effects.
Tryptase
Nowadays, it is the best routine biomarker available to assess MC activation. MC tryptase belongs to the family of MC serine proteases and is present in large amounts in secretory granules of human MCs [26] . Tryptase is highly specific of MC, so its detection provides information about MC distribution, number, activation status, or releasability. Tryptase is also produced in basophils but in much lower amounts [27, 28] . Sequential peak and baseline serum tryptase measurements help to detect mast cell activation. Levels are increased from 15 min to 3 h after anaphylaxis onset [29] or even longer [30] , with the peak between 1 and 2 h [30]. However, its involvement in angioedema has not been established.
Histamine
Histamine is the other biomarker available to assess MC activation; however, plasma histamine is quickly metabolized by Nmethyltransferase and diamine oxidase, its peaks within 5-10 min of the onset of symptoms and declines to baseline within 30 min [29] . Therefore, blood samples need to be obtained at the onset of symptoms, limiting its routine applicability. Histamine correlates with anaphylaxis severity [31] , but again, data regarding its involvement in AE-WoW or its usefulness for the diagnosis are lacking. Vasodilation and edema, mucus secretion, bronchoconstriction, and leukocyte recruitment PAF Platelet activation/μ thrombi, leukocyte migration, histamine release, reduce myocardial contractibility. Poorly involved directly in vasodilation and edema. Newly generated over hours Cytokines and chemokines Poorly involved directly in angioedema. Anaphylatoxins (C3a, C4a, C5a)
Complement activation products, mast cell degranulation, vasodilation and edema, and smooth muscle contraction.
LT leukotriene, PG prostaglandins, PAF platelet-activating factor
Heparin
This mediator may be involved in both types of angioedema, given that recently, Sala-Cunill et al. [7••] have reported the role of heparin in activating plasma contact system. They describe that IgE/antigen-stimulated MCs release heparin locally, which induces BK formation in a FXII-dependent manner in mice and also in human mast cell activation anaphylaxis. During anaphylaxis, patients presented a high-molecular-weight kyninogen cleavage with BK formation and high levels of anti-Xa (an indirect measure of plasma heparin) compared with controls. The study also suggests that activated MCs release heparin into circulation. This heparin, due to its negative charge, is a potent FXII contact activator in humans, inducing contact system-mediated BK formation in plasma. This BK will increase the vascular permeability. They also found a statistically significant correlation between the severity and BK levels [7••] . However, a routine validated method to measure BK directly does not exist. Therefore, its usefulness in the diagnosis of angioedema is unknown.
Cysteinyl leukotrienes and prostaglandins
Leukotriene C4 (LTC4) is the major 5-lipoxygenase product produced by activated MCs and basophils, although platelets, eosinophils, endothelial cells, and vascular smooth muscle cells also produce LTC4. It is rapidly metabolized to LTD4 and then to LTE4, which can be measured in urine [32] . Prostaglandin D2 (PGD2) is the main cyclooxygenase product produced by activated MCs but not by activated basophils. Like histamine and LTC4, clearance from the systemic circulation is rapid, and elevated serum levels are difficult to detect. Its metabolite (11-beta-PGF2-alfa) can be measured in urine and is more sensitive than N-methylhistamine [33] . However, measurement of PGD2 cannot be used in patients receiving cyclooxygenase inhibitors.
Both mediators can produce vasodilation and edema. However, nowadays, there is no routine laboratory method to measure them. In addition, both could be secreted by cells different from mast cell. Their usefulness in the diagnosis of angioedema has not yet been demonstrated.
Cytokines and chemokines
Most of these mediators propagate and/or regulate the immune response and seem poorly involved in direct vasodilation and edema.
Specific treatment options of angioedema without wheals: from old to novel therapies
According to the potential mechanisms involved in each AE type, different therapeutic approaches may be considered.
Mast cell/basophil-related angioedema
This group includes allergic AE, NSAIDS-AE, other drug-induced AE, and idiopathic AE responsive to antihistamines.
Antihistamines
The first line of treatment of acute angioedema in the emergency department is antihistamines and glucocorticoids. Also, removal of the offending agent is crucial in allergic or drug-induced angioedema [34] .
First-generation H1 antagonists are the only antihistamines available for intravenous infusion (dexchlorpheniramine, diphenhydramine) [35] . Second-generation H1 antagonists may also be given because they are safe and well tolerated with very few and mild side effects, although this would be limited to the oral route [36, 37] .
Glucocorticosteroids
There are no high-quality investigations assessing the use of glucocorticosteroids (GCS) in angioedema [38] . In fact, the optimal dose and duration of GCS treatment used for acute urticaria and angioedema have not been systematically studied, and the recommendations vary widely depending on the specialists and the countries [36] . However, when angioedema affects the respiratory airway, the use of steroids is beneficial in adults and in children [39] . In addition, GCS used in a short course for the acute attack are well tolerated and have few side effects.
Adrenaline
After a quick assessment, if a patient suffers an acute laryngeal edema, intramuscular adrenaline in the mid-anterolateral thigh may be lifesaving [35, 40] . However, transient pharmacologic side effects after a recommended dose may occur. These are pallor, tremor, anxiety, dizziness, headache, and tachycardia. Other serious adverse effects (such as ventricular arrhythmias) normally occur after an overdose.
Bradykinin-related angioedema
This group includes AAE-ACEi, AAE-C1INH, and HAE-C1INH (I and II), and probably HAE-nC1INH (HAE-FXII and HAE-unknown) and idiopathic unknown-AE. This type of angioedema does not respond to antihistamines, corticosteroids, or adrenaline [2••] . Recently, novel treatments have appeared for these types of angioedema, although we must keep in mind that much of the reported experience cited is from studies in HAE type I and II and further studies are needed to evaluate their efficacy in the others types of AE. [44] . Furthermore, the recent changes of product licences allowing self-administration provide additional options for the management of HAE and improve the quality of life of these patients [45] .
Recombinant human C1 esterase inhibitor concentrate -Ruconest ® (Pharming Group NV, Leiden, The Netherlands): 50 U/kg body weight up to 4200 U i.v. As the recombinant drug is produced by recombinant DNA technology in the milk of transgenic rabbits, it could induce allergic reactions in patients sensitized to rabbit dander. Thus, specific anti-rabbit IgE determination is recommended before using this product [2••, 46] .
Bradykinin receptor antagonist
-Icatibant acetate (Firazyr ® ; Shire Orphan Therapies, Berlin, Germany). European Public Assessment Report (EMEA 925383/ 2011) for Firazyr. 2011. Available at http://www.ema.europa.eu/ ema. Icatibant is a synthetic, decapeptide, short acting, and highly selective competitive BK B2 receptor antagonist, which inhibits the vasodilatation produced by BK. It is administered subcutaneously (30-mg/3-ml syringes). Its effectiveness has been shown in multiple clinical trials for patients with types I and II HAE [47, 48] and in case series in AAE-ACEi [49] . No serious adverse reactions have been reported.
Plasma Kallikrein inhibitor
-Ecallantide: (Kalbitor ® ; Dyax Corp., Cambridge, Mass, US). Ecallantide is a recombinant, 60-aminoacid protein synthesized in the yeast Pichia pastoris which acts as a specific, reversible inhibitor of plasma kallikrein, the serum protease that produces BK. It is administered subcutaneously (30 mg in three vials of 10 mg/ml) [50] . This inhibition helps to restore the balance between the production and degradation of BK. It is only approved by the FDA and not available in Europe [2] . Potentially serious hypersensitivity reactions, including anaphylaxis, occurred in 2.7 % of patients.
Antifibrinolytic agents -Tranexamic acid: (Amchafibrin ® : Rottapharm, Barcelona, Spain). These drugs can be effective in an angioedema attack, but they are only recommended when the previously described treatments are not available. There are no data based on controlled clinical trials. High intravenous (15 mg/kg/4 h iv) or oral doses of tranexamic acid have been used [2] , and it has proven effective in prodromal phases of the attacks [51] . The efficacy of tranexamic acid in the prevention of angioedema attacks of HAE-C1INH has been shown in early clinical trials [52] , and case series have also shown its effectiveness in the prophylactic treatment in idiopathic angioedema that does not respond to antihistamines [53, 54•, 55] .
Conclusions
In the last few years, progress about knowledge and treatment of angioedema has greatly improved. However, given that the different types of angioedema and the mechanisms involved are not fully understood, there are still many knowledge gaps that need to be overcome in order to improve the diagnosis, to be able to differentiate
